|
|
Volumn 20, Issue 2, 2002, Pages 121-124
|
|
Antisense and sensibility
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
MEDICINE;
RESEARCH;
ANTISENSE;
BIOTECHNOLOGY;
ADENOSINE A1 RECEPTOR;
ANTINEOPLASTIC AGENT;
ANTIRETROVIRUS AGENT;
ANTISENSE OLIGONUCLEOTIDE;
ANTIVIRUS AGENT;
COMPLEMENTARY DNA;
CYCLIC AMP DEPENDENT PROTEIN KINASE;
DNA;
FOMIVIRSEN;
MESSENGER RNA;
RIBONUCLEOTIDE REDUCTASE;
BIOTECHNOLOGY;
CANCER;
CANCER CHEMOTHERAPY;
CLINICAL TRIAL;
CYTOMEGALOVIRUS INFECTION;
DRUG INDUSTRY;
DRUG RESEARCH;
DRUG TARGETING;
HUMAN;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RESPIRATORY TRACT DISEASE;
RETINITIS;
REVIEW;
VIRUS INFECTION;
CYTOMEGALOVIRUS;
|
|
EID: 0036168035
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt0202-121 Document Type: Review |
|
Times cited : (69)
|
|
References (4)
|
